Source:http://linkedlifedata.com/resource/pubmed/id/11082464
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2000-12-20
|
pubmed:abstractText |
Recently, selective and systemically active antagonists for the metabotropic glutamate 5 receptor (mGlu(5)) were discovered, and the most potent derivative was found to be MPEP (2-methyl-6-(phenylethynyl)pyridine). Given the high expression of mGlu(5) receptors in limbic forebrain regions, it was decided to evaluate the anxiolytic potential of MPEP. After an acute oral administration, MPEP attenuated the anxiety-dependent variable in a variety of well established anxiety test paradigms. In rats, MPEP (10, 30, and 100 mg/kg) increased punished responses in the Geller-Seifter test, but none of these effects reached statistical significance. MPEP significantly increased the ratio (open/total arm entries; 0.1, 1, and 10 mg/kg), the number of open arm entries (0.1, 1, and 10 mg/kg), as well as time spent on open arm (0.1 and 1 mg/kg) in the elevated plus maze test. Furthermore, MPEP (0.3 and 1 mg/kg) significantly increased the time spent in social contact in the social exploration test. In mice, MPEP attenuated stress-induced hyperthermia (15 and 30 mg/kg) and decreased the number of buried marbles in the marble burying test (7.5 and 30 mg/kg). Finally, MPEP (0.01, 0.1, 1, 10, and 100 mg/kg) was tested on spontaneous locomotor activity in mice, and only a dose of 100 mg/kg significantly reduced vertical activity; no effect was seen on horizontal activity. MPEP (7.5, 15, and 30 mg/kg) was ineffective on d-amphetamine-induced (2.5 mg/kg) locomotor activity in mice and prepulse inhibition in rats (1, 3, or 10 mg/kg). Thus, these findings indicate that MPEP exhibits anxiolytic-like effects and low risks for sedation and psychotomimetic side-effects in rodents.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/6-methyl-2-(phenylethynyl)pyridine,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Anxiety Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Dextroamphetamine,
http://linkedlifedata.com/resource/pubmed/chemical/Excitatory Amino Acid Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Metabotropic Glutamate
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0022-3565
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
295
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1267-75
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11082464-Animals,
pubmed-meshheading:11082464-Anti-Anxiety Agents,
pubmed-meshheading:11082464-Body Temperature,
pubmed-meshheading:11082464-Dextroamphetamine,
pubmed-meshheading:11082464-Dose-Response Relationship, Drug,
pubmed-meshheading:11082464-Excitatory Amino Acid Antagonists,
pubmed-meshheading:11082464-Exploratory Behavior,
pubmed-meshheading:11082464-Male,
pubmed-meshheading:11082464-Maze Learning,
pubmed-meshheading:11082464-Mice,
pubmed-meshheading:11082464-Motor Activity,
pubmed-meshheading:11082464-Pyridines,
pubmed-meshheading:11082464-Rats,
pubmed-meshheading:11082464-Rats, Inbred BN,
pubmed-meshheading:11082464-Rats, Sprague-Dawley,
pubmed-meshheading:11082464-Rats, Wistar,
pubmed-meshheading:11082464-Receptors, Metabotropic Glutamate
|
pubmed:year |
2000
|
pubmed:articleTitle |
Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents.
|
pubmed:affiliation |
Novartis Pharma AG, Nervous System Research, Basel, Switzerland. willibrordus.spooren@pharma.novartis.com
|
pubmed:publicationType |
Journal Article
|